Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC

Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as nivolumab and pembrolizumab, has significantly improved the survival of patients with metastatic non-small cell lung cancer (NSCLC). In order to determine the subset of patients that can benefit most from these therapies, biomarkers such as programmed death ligand-1 (PD-L1) have been proposed. However, the predictive and prognostic role of the use of PD-L1 is controversial. Anti-PD-L1 immunohistochemistry may not represent the actual status of the tumour because of individual variability and tumour heterogeneity. Additionally, there may be analytical variability due to the use of different assays and antibodies to detect PD-L1. Moreover PD-L1 expression is also regulated by oncogenic drivers in NSCLC, such as epidermal growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4 (EML4) fusion with anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS). Preclinical studies have shown the potential role of targeted therapy in immune escape mechanisms in NSCLC cells. This review summarizes current literature data on the heterogeneity of PD-L1 expression and the relationship with such factors and with clinicopathological features of NSCLC.

[1]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[2]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[3]  T. Mitsudomi,et al.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[5]  F. Hodi,et al.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.

[6]  F. Guisier,et al.  Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer , 2017, Targeted Oncology.

[7]  N. Chen,et al.  KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma , 2017, Cancer Immunology, Immunotherapy.

[8]  K. Shimizu,et al.  PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer , 2017, Cancer Immunology, Immunotherapy.

[9]  J. Ahn,et al.  EGFR TKI combination with immunotherapy in non-small cell lung cancer , 2017, Expert opinion on drug safety.

[10]  H. Wang,et al.  Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[12]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[13]  J. Fujimoto,et al.  Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[15]  L. Gandhi,et al.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[16]  D. Carbone,et al.  Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Dong-Wan Kim,et al.  Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. , 2016, Clinical lung cancer.

[18]  Tianhong Li,et al.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy , 2016, Journal of Hematology & Oncology.

[19]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[20]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[21]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[22]  Y. Huang,et al.  Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients , 2016, Oncoimmunology.

[23]  N. Chen,et al.  Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer , 2016, Scientific Reports.

[24]  M. Socinski,et al.  Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma , 2015, Experimental Hematology & Oncology.

[25]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[26]  Bernard A. Fox,et al.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.

[27]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[28]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[30]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[31]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[32]  Ge Li,et al.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs , 2015, Oncotarget.

[33]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[34]  A. Chella,et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients , 2014, British Journal of Cancer.

[35]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[36]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Meyerson,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[38]  Liu Wang,et al.  Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. , 2013, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[39]  Clive R. Taylor,et al.  Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). , 2013 .

[40]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[41]  C. Mu,et al.  High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation , 2011, Medical oncology.

[42]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[43]  A. Aboussekhra,et al.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.

[44]  R. Nurieva,et al.  Yin–Yang of costimulation: crucial controls of immune tolerance and function , 2009, Immunological reviews.

[45]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[46]  Ping Zhang,et al.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.

[47]  S. Jabbour,et al.  Current state of immunotherapy for non-small cell lung cancer. , 2007, Translational lung cancer research.

[48]  I. Wistuba,et al.  Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  L. Siu,et al.  PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. , 2016, JAMA oncology.

[50]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[51]  Y. Nakanishi,et al.  Induction of PD-L 1 Expression by the EML 4 – ALK Oncoprotein andDownstreamSignalingPathways in Non – Small Cell Lung Cancer , 2015 .

[52]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.